We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment.
- Authors
Rodrigues-Junior, Dorival Mendes; Biassi, Thaís Priscila; De Albuquerque, Gabriela Estrela; Carlin, Viviane; Buri, Marcus Vinicius; Machado-Junior, Joel; Vettore, Andre Luiz
- Abstract
Multiple myeloma (MM) is an incurable disease; a better understanding of the molecular aspects of this hematological malignancy could contribute to the development of new treatment strategies and help to improve the survival rates of patients with MM. Previously, the methylation status of the deleted in colorectal cancer (DCC) gene was correlated with the survival rate of patients with MM, thus the main goal of this study was to understand DCC contribution to MM tumorigenesis, and to assess the impact of DCC inhibition in the MM response to treatment with bortezomib. Our results demonstrated that hypermethylation of the DCC promoter inhibits gene expression, and DCC silencing is significantly correlated with a reduction in cell viability and an increase in cell death induced by bortezomib. In conclusion, our results suggested that hypermethylation is an important mechanism of DCC expression regulation in MM and that the absence of DCC contributes to the enhanced sensitivity to treatment with bortezomib.
- Subjects
MULTIPLE myeloma; HEMATOLOGY; COLON cancer; BORTEZOMIB; CELL death
- Publication
Molecular Medicine Reports, 2019, Vol 19, Issue 6, p5023
- ISSN
1791-2997
- Publication type
Article
- DOI
10.3892/mmr.2019.10142